

Syngene

Putting Science to Work

Discovery Services

Science
For People
**ADVANCING
INNOVATION**

Connected Expertise Across
Modalities, Therapeutic
Areas, and Discovery Stages



30+ Years of Putting Science to Work



A Global CRDMO

Integrated drug discovery, development and manufacturing service provider.

Small molecules and biologics, ADCs, oligonucleotides.

Listed on Indian stock exchanges (NSE and BSE).



Scientific Ecosystem

3 Mn sq. ft. world-class R&D and manufacturing infrastructure.

Sites in Bangalore, Mangalore, and Hyderabad.

~6000 qualified scientists including 530 PhDs.

Highly effective supply chain practices.



IP Position

IP assigned to clients.

Strong track record of data integrity and security.

Over 400 patent assignments by clients recognizing Syngene.



Marquee Clients

400+ active clients last FY.

Partnering with large / mid-size / emerging bio-pharma (EBP), and other industries.

Clients concentrated in U.S., Europe and Japan.

Track record of working with diverse industry sectors.



Quality Focus

Quality driven organization.

Excellent track record of compliance with global regulators.

USFDA, EMA, ANVISA, and PMDA-approved, GLP-certified, Ministry of Health of Russian Federation, AAALAC, and CAP accredited / certified facilities.

15+ regulatory and 160+ client audits in the last 3 years.



Track Record

Collaborations and partnerships to deliver numerous clinical candidates.

Delivery history for integrated CMC programs towards FIH and beyond.

SynVent Integrated Drug Discovery

Across Multiple Therapeutic Areas and Modalities to Drive Innovation and Speed

Therapeutic Areas

- Oncology
- Immunology
- Neuroscience
- Infectious diseases
- Cardiovascular and metabolism
- Inflammation
- Rare / orphan diseases

Modalities

- Small molecules
- Peptides
- Oligonucleotides
- Antibodies
- Antibody drug conjugates
- PROTACs
- CAR-Ts

Drug Discovery at a Global Scale

1600

Scientists, with
95 %+ MS / PhDs

600,000

Sq. Ft. of Lab Space

200+

Global Clients

Efficiency Through Co-Localization of Team Members and Capabilities

- IDD programs for 8 clients over 6 therapeutic areas
- Syngene-SynVent for therapeutic discovery on behalf of clients
- High rate of repeat business and return clients



Realize Your Next


Drug Candidate Through Our Chemistry, Biology and Biotherapeutics, Safety / Tox, and Computational and Data Sciences

- 95 % on-time delivery rate for known target compounds, >90 % for unknown targets
- 25,000 reagents and 8000 unique scaffolds in stock
- LCMS lab with ability to perform 96,000 analyses/year and access to NMR lab to run 25,000 samples/year
- High-throughput mass based preparative HPLC lab for purifications with current capacity of 30,000 compounds/year
- Completed ~40 PROTACs libraries (>98 % success rate)
- 5000+ compounds in HT ADME assays/year
- 2500+ rodent (n=3) PK studies/year
- ADME studies turnaround in ~10 calendar days with >95 % TAT adherence
- Computational and data sciences support across multiple stages of the discovery paradigm
- Effective use of CADD, cheminformatics and AI for multiparametric optimization
- Fully automated central compound management facility that provides a seamless link between chemistry and biology operations




Discovery Toolbox

We have the capabilities to apply the most appropriate modality for target validation and therapeutic discovery.


 Small Molecules, Peptides	 Oligonucleotides	 Antibodies	 Antibody-Drug Conjugates (ADCs)	 Proteolysis Targeting Chimeras (PROTACs)	 Chimeric Antigen Receptor T-Cells (CAR-Ts)
---	---	---	--	--	---

End-to-End Discovery Platform

Our end-to-end platform allows us to offer integrated as well as standalone services across the discovery continuum.




We deliver our services (both integrated & functional) via a range of proven collaboration models.



Discovery Chemistry

Discovery Chemistry at Syngene is delivered by 1500+ highly qualified scientists, backed by strong analytical chemistry support, robust IT infrastructure and ELN, as well as efficient data and compound management



Discovery Biology and Biotherapeutics

The discovery biology and biotherapeutics team supports drug discovery across multi-modal platforms including small and large molecules as well as cell and gene therapy, across multiple therapy areas. Our diverse team of scientists solve complex biological problems in an integrated fashion, embracing scientific excellence, operational efficiency, and commercial competitiveness.




700+
Scientists




110,000
sq. ft. Lab Space state-of-the-art Infrastructure



Protein Sciences




Cell Engineering



Antibody Discovery and Engineering



Genomics and Translational



Assay biology & Screening



ADME-PK



In Vivo Pharmacology

Compound Management Services

Syngene offers a comprehensive, fully automated, state-of-the-art, centralized compound management (CCM) that ensures material integrity, traceability, accessibility, and efficiency in dispensing.


Compounds / Samples




Compound Registration System

Compound ID-barcode Fingerprinting

Syngene's Central Compound Management



Testing Laboratories



Solid Storage Capacity: 70,000 compounds

Liquid Storage Capacity: >0.3 million tubes in high-density racks with additional scope for expansion by 3X

Automated Compound Storage System:

- Hamilton verso at 4 °C
- Hamilton verso at -20 °C

Liquid Handling Systems:

- Fluent from Tecan integrated with capper / decapper from Hamilton and plate seal
- ECHO 650





Safety Assessment Services

Full range of toxicology services for comprehensive nonclinical development of pharmaceuticals.

Exploratory Studies	GLP Studies	Phase I	Phase II	Phase III	Specialty Studies
Pharmacokinetics	Analytical and bioanalytical studies to support safety tox program	GLP repeat dose studies & genetic toxicology	Sub-chronic toxicity study		<i>In Silico</i> & risk assessment
	Repeat dose toxicology (2 species)				Nitrosamine (NDSRI) assessment
(MTD / dose escalation / short-term repeat dose)	Genotoxicity (<i>In Vitro</i> / <i>In Vivo</i>)		Reproductive toxicology (fertility/ pre and postnatal & embryofetal development)		Predictive tox
Genotoxicity screening (<i>In Vitro</i>)	Toxicokinetics		Chronic toxicology & carcinogenicity		ICHM7, & impurity qualification
Safety pharmacology: CNS, respiratory, CV	Core battery safety pharmacology				Extractables & leachables
	Reproductive toxicology (Seg I, Seg II, & Seg III)				PDE & OEL reports
					<i>In Vitro</i>
					Cytotoxicity
					Skin sensitization / irritation
					Phototoxicity
					<i>In Vivo</i>
					Impurity qualification
					Medical device / ISO-10993
					Dermal tox
					Local tolerance
					Phototoxicity

Computational and Data Sciences Capabilities

Syngene's computational and data sciences capabilities enable informed decisions at all stages of the drug discovery continuum.



Syngene
Putting Science to Work

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated CRDMO (Contract Research, Development and Manufacturing Organization), serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's ~6000 scientists bring the skills and capacity to deliver great science, strong data security, and quality manufacturing, at speed, helping improve time-to-market and lower the cost of innovation. This is backed by ring-fenced dedicated centers, as well as ~3 Mn sq. ft. of specialist discovery, development, and manufacturing facilities.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com